galsulfase
Selected indexed studies
- Galsulfase. (, 2006) [PMID:39190731]
- ** (, 2016) [PMID:28121110]
- Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. (Cochrane Database Syst Rev, 2021) [PMID:34533215]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Galsulfase. (2006) pubmed
- PMID:28121110 (2016) pubmed
- Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. (2021) pubmed
- Galsulfase. (2006) pubmed
- Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. (2016) pubmed
- Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB. (2005) pubmed
- Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: Systematic review. (2019) pubmed
- Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database. (2024) pubmed
- Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI. (2014) pubmed
- Mucopolysaccharidosis VI. (2010) pubmed